StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Rating) in a research note issued to investors on Sunday. The firm issued a sell rating on the stock.
Ampio Pharmaceuticals Stock Performance
AMPE traded down $0.03 during trading on Friday, reaching $0.26. 101,985 shares of the stock were exchanged, compared to its average volume of 282,602. Ampio Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $3.45.
Ampio Pharmaceuticals (NYSE:AMPE – Get Rating) last released its quarterly earnings data on Monday, May 8th. The company reported ($0.26) EPS for the quarter.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.
Further Reading
- Get a free copy of the StockNews.com research report on Ampio Pharmaceuticals (AMPE)
- Can Cardinal Health Fly Higher In 2023?
- DraftKings Stock, Is There Royally Good Upside Ahead?
- Disney Stock Could Double: Return To Historical Performance
- For AI Exposure, Try Global Artificial Intelligence ETF
- 3 Penny Stocks The Insiders Are Buying
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
